Investor Newsletter

Issue 06 2022

MicroPort®

MicroPort® Meets Global Industry Experts and Scholars in Paris and Presents Several Products at EuroPCR 2022

The Congress of European Association for Percutaneous Cardiovascular Interventions (EuroPCR 2022) was held in-person for the first time since the COVID outbreak and MicroPort Scientific Corporation ("MicroPort®") took the opportunity to introduce its product portfolio to a global audience recently. On location in Paris, MicroPort®, together with its subsidiaries Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort® Coronary") and Shanghai MicroPort CardioFlow Medtech Corp ("CardioFlow Medtech"), showcased its rapamycin target eluting coronary stent systems Firehawk® and Firehawk Liberty™; Firefighter™ PTCA and NC balloon dilatation catheters; the VitaFlow Liberty™ transcatheter aortic valve and retrievable delivery system; and the MicroPort® Argus™ OCT System endoluminal imaging solution.

In addition to the meeting, many international cardiologists visited the MicroPort® exhibition booth at the venue, ably supported on site by the MicroPort® CRM team in France. Through this conference, MicroPort® once again presented its diverse product lines to global experts. The unique technology in MicroPort® products is sure to expand the choices and confidence of patients and doctors because of the great benefits for coronary artery disease.

MicroPort

MicroPort® Releases 2-Year Results of Firesorb® Pivotal Trial FUTURE II

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”) recently released the 2-year clinical follow-up results from the pivotal FUTURE II trial of its self-developed, second-generation, fully bioresorbable vascular scaffolds system - Firesorb® Bioresorbable Rapamycin Targeted Eluting Coronary Scaffold System ("Firesorb®").

Prof. Bo Xu commented: "The randomized clinical data of future II shows that the safety and reliability of Firesorb® at the 2-year traditional endpoints are fully comparable with the top bland of metal drug-eluting stents, and no late catch-up effect is found, which is a very exciting discovery. It shows that, in addition to the excellent clinical effect of drug-eluting stents, this kind of fully bioabsorbable scaffold can greatly improve the quality of life of patients. This result gives doctors more confidence in using Firesorb® to treat the patient." Prof. Bo Xu also revealed that: "Firesorb® another large-scale pivotal clinical trial, Future III, is in the 1-year follow up stage. We are looking forward to the early launch of Firesorb® for the benefit of patients."

“The 2-year results of the FUTURE II study continue the previous positive performance and further confirm the efficacy and safety of Firesorb® to be fully comparable to the world's top competing products" said Mr. Qiyi Luo, Chief Technology Officer of MicroPort®. “We are excited by this result, and it has increased people’s expectation for this new generation of biodegradable coronary scaffolds. We hope to provide patients and doctors with more choices and confidence through sustained long-term and rigorous product research and clinical research, so as to benefit more patients with coronary artery disease worldwide."



MicroPort

MicroPort Argus™ OCT System Officially Launched

Fourteen of China's top interventional came together to launch the MicroPort Argus™ OCT System at the 16th Oriental Congress of Cardiology. The online launch event titled "Vastness and diminutiveness in sight" was hosted by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®").

Mr. Lei Jiang, President of MicroPort® Coronary, also brought his perspective to the event: "Focusing on the OCT system solution, we have made breakthroughs and obtained several first-of-its-kind technologies in the field of OCT, and have filed over 50 patent applications, which results in the development of the MicroPort Argus™ OCT system, the only purge-free OCT imaging catheter in China. MicroPort® has always carried its mission and responsibility to provide targeted innovation based on clinical needs. We insist on independent research and development to deepen medical–industrial cooperation and unlock the power of innovation. By providing more innovative technologies and superior products, we will be able to provide accessible and inclusive solution to prolong and reshape the lives of patients with coronary heart disease."

Endovastec™ Reewarm™ PTX DCB PTA Catheter Receives Marketing Approval in Brazil

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™") today announced that it has received registration approval from the Brazilian Health Regulatory Agency (ANVISA) for its independently developed Reewarm™ paclitaxel (PTX) drug-coated balloon (DCB) percutaneous transluminal angioplasty (PTA) Catheter ("Reewarm™ PTX").

Mr. Qing Zhu, President of Endovastec™, stated: "The Reewarm™ PTX has shown excellent clinical performance since its launch. It has provided a better surgical solution for the treatment of peripheral artery diseases, and elevated our market competitiveness in the field of peripheral vascular intervention. In the future, Endovastec™ will continue to develop and produce more high-quality, high-end medical devices to benefit more patients worldwide."

MicroPort

MicroPort NeuroTech™ Completes First Implantation of Numen™ Coil Embolization System in the U.S.

MicroPort Neurotech Limted ("MicroPort NeuroTech™"), a pioneering Chinese company in the field of neurovascular interventional treatment, today announced it has successfully completed the first commercial implantation with its independently developed Numen™ Coil Embolization System ("Numen™") in the United States.

"The first implantation of Numen™ in the U.S. is a key step for the Company to enter the U.S. market." Commenting on the news, Mr. Bruce Wang, Executive Director and Executive Vice President of MicroPort NeuroTech™ stated, "It also marks a deepening cooperation between MicroPort NeuroTech™ and Rapid Medical. We cannot wait to work closely with Rapid Medical and make our innovative products more diversified and accessible, to benefit more international patients."

Mr. Zhiyong Xie, Executive Director and President of MicroPort NeuroTech™, stated, "The successful surgery strengthened our confidence to further expand our global presence. The U.S. market is not only one of the most important markets globally, but also playing an increasingly important role in our R&D and academic collaboration. MicroPort NeuroTech™ will continue to follow our brand ideology of 'The Patient Always Comes First' and strive to provide more premium solutions to treat neurovascular diseases for patients and doctors around the world. "

MicroPort

CardioFlow Medtech's Strategic Partner, 4C Medical, Releases Global Clinical Data on Early Feasibility Study of AltaValve™ Transcatheter Mitral Valve Replacement at AATS 2022

MicroPort CardioFlow Medtech Corporation (hereafter referred to as "CardioFlow Medtech") announced that its strategic partner, 4C Medical Technologies, Inc. ("4C Medical") recently presented global clinical experience and data on the early feasibility study (EFS) of its innovative transcatheter mitral valve implant replacement (TMVR), AltaValve™, at the Mitral Valve Symposium of American Association for Thoracic Surgery (AATS) in Boston on May 13, 2022.

Dr. Krzysztof Wrobel, a cardiac surgeon at Medicover Hospital in Warsaw, Poland, presented his clinical experience with AltaValve™ at AATS 2022: "Based on our initial clinical experience, the AltaValve™ transapical approach procedure is simple and easy to perform, with clinically significant reduction in mitral regurgitation. The long-term follow-up results of AltaValve™ are very encouraging, and no thrombosis or erosion of the implant, permanent pacemaker implantation or other device-related problems have been observed in this cohort of patients. We are collecting additional clinical data, including transseptal access cases, to further build on this experience."

MicroPort® MedBot® Announces the Completion of R-One® Vascular Interventional Surgical Robot Registrational Clinical Trial

Cathbot (Shanghai) Robot Co., Ltd. (hereafter referred to as "Cathbot") announced today that all surgeries under the registration clinical trial for the R-ONE® Vascular Interventional Surgical Robot (hereafter referred to as "R-ONE®") have been completed, making it the first vascular interventional robotic system to complete a large-scale clinical trial in China.

Dr. Chao He, President of MicroPort® MedBot®, said: "The completion of the multicenter clinical trial for the R-ONE® Vascular Interventional Surgical Robot is a major milestone for MicroPort® MedBot® in the pan-vascular intervention field. It is of great significance in driving the development of more precise and intelligent vascular interventions. In the future, robots for vascular interventions will be equipped with 5G and AI technologies. They will accomplish more breakthroughs when combined with angiography and hemodynamic monitoring and other technologies. Meanwhile, with the advantage of group-based operation, MicroPort® MedBot® will partner with more academic experts nationwide to promote high-quality medical resources to primary hospitals, and will provide more patients with precise, intelligent, and inclusive robotic surgical solutions."

Toumai® Completes the World's Longest-Range 5G Tele-Robotic Surgery

The Toumai® Laparoscopic Surgical Robot ("Toumai®"), independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot®") successfully completed two ultra-long-range 5G robotic surgeries in urology through 5G connection between Xinjiang Kezhou People's Hospital and Jiangsu Provincial People's Hospital. These two surgeries were nearly 5,000 km apart, making them the longest 5G remote robotic surgeries in the world to date.

According to Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®, "Toumai®, supported by 5G technology, enables doctors to 'see thousands of miles and perform from thousands of miles away'. Doctors have to perform on site in conventional surgical operations, but the 5G transmission technology allows surgeons arms to extend thousands of miles, which greatly expands their surgical space; at the same time, it is also conducive to the utilization of high-quality medical resources, narrowing the gap of treatment at different levels of hospitals and reducing the economic burden of patients. MicroPort® MedBot® will continue to strive towards facilitating surgeries worldwide."

MicroPort

Hemovent™ Showcases Product Portfolio on 10th EuroELSO congress in London

Hemovent GmbH (hereafter referred to as "Hemovent™") has successfully showcased its product portfolio for the first time under its new MicroPort® flag at the 10th EuroELSO Congress in London, UK.

Hemovent™ took the opportunity to present its unique extracorporeal life support (ECLS) MOBYBOX® system, which is the first extracorporeal membrane oxygenation (ECMO) device to integrate both blood flow control and gas management into a single device. "We are extremely proud to now be a part of MicroPort® and to build on the profound resources, industry expertise, and global reach to raise our unique technology to the next level. We are looking forward to scaling our commercial activities, ramping up operations, and extending our product portfolio as a MicroPort® innovation lab", said Christof Lenz, CEO of Hemovent™.

CERTIFICATE

This is to certify that the company

Hemovent GmbH

Pascalstrasse 59
52076 Aachen
Germany

with the organizational units/sites as listed in the annex

has implemented and maintains a **Quality Management System**.

Scope of certification:
Design, Development, Production, Service and Distribution of Systems for extracorporeal membrane oxygenation.
-CND, USA (a,b,c,d,e)

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485 : 2016

including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no.	534936 MDSAP16
Certificate unique ID	170724181
Effective date	2022-05-03
Expiry date	2025-05-02
Frankfurt am Main	2022-05-03

MDSAP MEDICAL DEVICE SINGLE AUDIT PROGRAM

DQS Medizinprodukte GmbH

Sigrid Uhlemann
Managing Director

Szymon Kurdyn
Product Manager

August-Schanz-Straße 21, 60433 Frankfurt am Main,
Tel. +49 (0) 69 95427-300, medical.devices@dqs-med.de
DQS Medizinprodukte GmbH is recognized under the Medical Devices Single Audit Program.
Visit https://www.dqs.de/en/customer-database/ to validate this certificate.

1 / 3

413_01 Version 6.0

IQNet

Hemovent™ Receives MDSAP Certificate for United States and Canada

Hemovent GmbH (hereafter referred to as "Hemovent™") has received a Medical Device Single Audit Program (MDSAP) certificate from the DQS Medizinprodukte GmbH (DQS), an international notified body. This certifies Hemovent™'s compliance with both ISO 13485:2016 standards and the regulatory requirements in the United States and Canada, laying groundwork for the company's future global development and growth.

"We are proud to have internationally expanded full ISO 13485:2016 QMS certification, which demonstrates our ability to provide medical devices that consistently meet customer and applicable regulatory requirements," commented by Christof Lenz, CEO of Hemovent, "Obtaining the MDSAP quality system certificate will pave the way for Hemovent™'s ambitious future expansion plans to international markets."

MicroPort

Investor Newsletter

Issue 06 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com